Riskpilot← Back to searchSign inGet full accessSynos Medical AB
ABActiveOrg 5568718075Sparrevägen 3Wholesale of pharmaceutical and medical goods · NACE 4646Est. 201110-19 employees
Revenue 2024
SEK 26M
+6% vs 2023
EBITDA margin
5.4%
+184% vs 2023
Equity ratio
42.0%
Financial strength
Net profit 2024
SEK 1,2M
+206% vs 2023
| Revenue | SEK 26M | +6% |
| EBITDA | SEK 1,4M | +184% |
| Net profit | SEK 1,2M | +206% |
| Total assets | SEK 5,9M | +44% |
| Equity | SEK 2,5M | +98% |
| Employees | — | — |
Legal name
Synos Medical AB
Org number
5568718075
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 november 2011
Share capital
SEK 50 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva försäljning, även på franchisebasis, av klinikutrustning för hårtransplantation och hårborttagning jämte därmed förenlig verksamhet. Företaget bedriver även flyttverksamhet som sidoverksamhet.
Address
Sparrevägen 3
Email
info@synos.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 405 | 11 873 | 29 750 | 24 489 | 26 021 |
| Staff expenses | — | — | −5 352 | — | −7 330 |
| EBITDA | 546 | 511 | 1 767 | −1 694 | 1 418 |
| Depreciation & amort. | −337 | −250 | −202 | −107 | −6 |
| EBIT | 209 | 261 | 1 565 | −1 801 | 1 411 |
| Net financials | −5 | −4 | −24 | −2 | −12 |
| Profit before tax | 149 | 257 | 1 126 | −1 153 | 1 299 |
| Tax | −36 | −51 | −257 | −0 | −72 |
| Net profit | 113 | 206 | 868 | −1 153 | 1 227 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 898 | 4 863 | 4 991 | 4 092 | 5 891 |
| Equity | 1 328 | 1 534 | 2 402 | 1 250 | 2 477 |
| Long-term debt | 0 | 0 | — | 0 | — |
| Short-term debt | 335 | 3 095 | 1 938 | 2 842 | 3 314 |
| Total debt | 335 | 3 095 | 1 938 | 2 842 | 3 314 |
EBITDA margin
5.4%
This company
15.8%
Market median
-66% vs market
20202024
Equity ratio
42.0%
This company
38.2%
Market median
+10% vs market
20202024
Return on equity
49.5%
This company
18.4%
Market median
+169% vs market
20202024
Net profit margin
4.7%
This company
8.1%
Market median
-42% vs market
20202024
Asset turnover
4.42×
This company
1.12×
Market median
+295% vs market
20202024
Debt / equity
1.38×
This company
0.62×
Market median
-123% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AT Chief Executive Officer | Chief Executive Officer | 2022 |
CH Audit | Audit | 2024 |
| Former (1) | ||
EC Chief Auditor | Chief Auditor | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Synos Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Cecilia Larsson | Chief Auditor | 0 companies |
| Andreas Tanzi | Chief Executive Officer | 0 companies |
| Carl Hampus Norberg | Audit | 0 companies |
| Matilda Linnea Grönborg Tanzi | Deputy Board Member | 0 companies |